Exhibition Review | Anke Bios PSEP Detection Products Debut at HTNC Investment Conference, Drawing Significant Industry Attention!

On 20 September, the HTNC Expo 2025 ‘Home Testing & New Consumer Healthcare Channels Investment Conference’, jointly organised by IVD Practitioners Network and others, concluded in Shenzhen.

The conference focused on transformation pathways for the IVD industry, attracting numerous industry experts, enterprises and channel partners. Angke Biomedical Technology (Suzhou) Co., Ltd. showcased its exclusive proprietary Prostate Secreted Protein (PSEP) detection series products, emerging as one of the event's focal points.

Featured Presentation: PSEP Technology Gains Widespread Recognition for Its Value

At 9:30 am on 20 September, the R&D Director of Angke Biotech delivered a keynote address entitled ‘PSEP: A Novel Biomarker for Prostate Disease Detection’. The venue was filled to capacity, with attendees including distributors, representatives from medical institutions, and industry investors. The presentation systematically outlined the clinical value and developmental prospects of PSEP testing across dimensions such as technological advantages, clinical data, and application scenarios, prompting active engagement and expressions of cooperation from participants.

Exhibition Stand Scene: A steady stream of professionals, with PSEP testing sparking lively discussion.

展会期间，昂科生物展区人流密集，检验科、泌尿外科、健康管理等领域专业观众驻足咨询，围绕PSEP检测的技术原理、临床场景及合作模式深入交流。

Several attending experts indicated that PSEP, as a novel diagnostic marker for prostate diseases, demonstrates significant potential for development in early screening and health management sectors, particularly suited for home self-testing and consumer healthcare applications.

Working Together for Mutual Success: Strengthening the Foundation for Market Expansion

Through this exhibition, Angke Bio not only showcased its biomedical technology R&D capabilities but also reached preliminary cooperation agreements with multiple regional distributors, chain health screening institutions, and internet health platforms, laying the groundwork for subsequent product market expansion.
Moving forward, Angke Bio will continue to deepen its technological footprint and accelerate product commercialisation. Collaborating with industry partners, it will drive innovative applications of IVD in health management and emerging consumer healthcare sectors, promote the widespread adoption of prostate health screening technologies, and inject momentum into the transformation and upgrading of China's IVD industry.